account_balance
Investment manager · 13F filer · SEC CIK 1855655
Paradigm Biocapital Advisors LP
Reported value$5.34Bas of Jun 30, 2026
Positions28 7 new, 14 sold out
Top 10 weight75.2%RVMD alone is 22%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
RVMDRevolution Medicines Inc
22.3%Trimmed −4%
NUVLNuvalent Inc
13.7%Added +11%
EWTXEdgewise Therapeutics Inc
7.8%Added +39%
GMABGenmab A/s
6.8%Added +65%
SYRESpyre Therapeutics Inc
6.4%Added +96%
APGEApogee Therapeutics Inc
3.9%Added +17%
ORKAOruka Therapeutics Inc
3.8%Trimmed −8%
TNGXTango Therapeutics Inc
3.7%Added +59%
BLTEBelite Bio Inc
3.6%Added +11%
ERASErasca Inc
3.3%Trimmed −8%
TARSTarsus Pharmaceuticals Inc
3.3%Added +8%
ALNYAlnylam Pharmaceuticals Inc
2.7%New
RVMDRevolution Medicines Inc
22.3%Trimmed −4%
NUVLNuvalent Inc
13.7%Added +11%
APGE3.9%
ORKA3.8%TNGX3.7%BLTE3.6%ERAS3.3%TARS3.3%ALNY2.7%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
RVMD Revolution Medicines Inc 22.3% Trimmed −4%
NUVL Nuvalent Inc 13.7% Added +11%
EWTX Edgewise Therapeutics Inc 7.8% Added +39%GMAB Genmab A/s 6.8% Added +65%SYRE Spyre Therapeutics Inc 6.4% Added +96%APGE Apogee Therapeutics Inc 3.9% Added +17%
ORKA Oruka Therapeutics Inc 3.8% Trimmed −8%TNGX Tango Therapeutics Inc 3.7% Added +59%BLTE Belite Bio Inc 3.6% Added +11%ERAS Erasca Inc 3.3% Trimmed −8%TARS Tarsus Pharmaceuticals Inc 3.3% Added +8%ALNY Alnylam Pharmaceuticals Inc 2.7% NewWhat changed